Bradford B. Walters

Vice President and Chief Medical Officer


  • PhD, University of London, Anatomy and Embryology,
  • MD, Harvard Medical School/Massachusetts Institute of Technology Division of Health Sciences and Technology
  • MBA, University of North Carolina at Chapel Hill, Kenan-Flagler Business School
  • AB, Harvard College, Chemistry and Physics

Serving as an internal consultant to cross-institute projects, Brad Walters, MD, PhD, MBA, has helped shepherd internal drug candidates into clinical trials, bringing three new chemical entities through the Investigational New Drug process of the FDA into five Phase 1 trials.

He also serves as Chairman of the Infectious Disease Advisory Group; as a member of the Board of Directors and Executive Committee of the RTI Press; as a member of the RTI Risk Management Committee and the Health, Environment, Risk, Safety, and Security Committee; and as a member of the Intellectual Property Commercialization Board. In 2014 and 2015, he has served on the North Carolina Board of Science and Technology.

Currently Dr. Walters is the principal investigator on a U.S. Army Medical Research Acquisition Activity grant to study the effectiveness and acceptability of a stellate ganglion block for treatment of posttraumatic stress disorder symptoms. He also serves on the Committee for the Protection of the Rights of Human Subjects at UNC-Chapel Hill and as RTI co-principal investigator in the partnership with the NC TraCS Institute/UNC-Chapel Hill Clinical and Translational Science Award from the National Institutes of Health.

Earlier in his career, after completing his PhD, MD, a surgical internship, and a neurosurgical residency, Dr. Walters assisted in establishing the radiosurgery program and the epilepsy surgery program as a member of the faculty of the University of North Carolina at Chapel Hill School of Medicine.

After completing his MBA, he joined Academy Funds, serving as principal and then partner, and on the boards of directors of Kucera Pharmaceutical Company, ParinGenix, and Curry Pharmaceuticals. He was then appointed a member of the Building Entrepreneurial Companies Work Group of the North Carolina Biotechnology Center Strategic Plan, and to the Governor’s Task Force on Nanotechnology and North Carolina’s Economy. From 1999 through 2006, he served as a member of the board of directors at NCHICA.